Skip to main content
Erschienen in: Zeitschrift für Rheumatologie 2/2016

01.08.2016 | Gicht | Leitlinie

Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)

Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh)

verfasst von: Dr. med. U. Kiltz, Dr. med. R. Alten, Prof. Dr. med. M. Fleck, Prof. Dr. K. Krüger, Prof. Dr. med. B. Manger, Prof. Dr. med. U. Müller-Ladner, Prof. Dr. med. H. Nüßlein, Prof. Dr. med. M. Reuss-Borst, Prof. Dr. med. A. Schwarting, Prof. Dr. med. H. Schulze-Koops, Dr. med. A. Tausche, Prof. Dr. med. J. Braun

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 2/2016

Einloggen, um Zugang zu erhalten

Auszug

Convenor: Prof. Dr. J. Braun …
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Kuo CF et al (2014) Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 74(4):661–667 PubMedPubMedCentralCrossRef Kuo CF et al (2014) Rising burden of gout in the UK but continuing suboptimal management: A nationwide population study. Ann Rheum Dis 74(4):661–667 PubMedPubMedCentralCrossRef
6.
Zurück zum Zitat Kuo CF et al (2015) Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662 PubMedCrossRef Kuo CF et al (2015) Global epidemiology of gout: Prevalence, incidence and risk factors. Nat Rev Rheumatol 11(11):649–662 PubMedCrossRef
7.
8.
Zurück zum Zitat Wallace KL et al (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31(8):1582–1587 PubMed Wallace KL et al (2004) Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 31(8):1582–1587 PubMed
9.
Zurück zum Zitat Annemans L et al (2008) Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67(7):960–966 PubMedCrossRef Annemans L et al (2008) Gout in the UK and Germany: Prevalence, comorbidities and management in general practice 2000–2005. Ann Rheum Dis 67(7):960–966 PubMedCrossRef
10.
Zurück zum Zitat Jing J et al (2014) Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: The German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. doi: 10.​1093/​ndt/​gfu352 PubMed Jing J et al (2014) Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: The German Chronic Kidney Disease (GCKD) study. Nephrol Dial Transplant. doi: 10.​1093/​ndt/​gfu352 PubMed
11.
Zurück zum Zitat Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125(7):679–687.e1 PubMedCrossRef Zhu Y, Pandya BJ, Choi HK (2012) Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007–2008. Am J Med 125(7):679–687.e1 PubMedCrossRef
12.
Zurück zum Zitat Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82(3):421–426 PubMedCrossRef Campion EW, Glynn RJ, DeLabry LO (1987) Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 82(3):421–426 PubMedCrossRef
14.
Zurück zum Zitat Bomalaski JS, Lluberas G, Schumacher HR Jr. (1986) Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 29(12):1480–1484 PubMedCrossRef Bomalaski JS, Lluberas G, Schumacher HR Jr. (1986) Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 29(12):1480–1484 PubMedCrossRef
15.
Zurück zum Zitat Dalbeth N, Stamp L (2014) Hyperuricaemia and gout: Time for a new staging system? Ann Rheum Dis 73(9):1598–1600 PubMedCrossRef Dalbeth N, Stamp L (2014) Hyperuricaemia and gout: Time for a new staging system? Ann Rheum Dis 73(9):1598–1600 PubMedCrossRef
16.
Zurück zum Zitat Gutman AB (1973) The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum 16(4):431–445 PubMedCrossRef Gutman AB (1973) The past four decades of progress in the knowledge of gout, with an assessment of the present status. Arthritis Rheum 16(4):431–445 PubMedCrossRef
17.
Zurück zum Zitat Khanna PP et al (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 10:117 PubMedPubMedCentralCrossRef Khanna PP et al (2012) Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes 10:117 PubMedPubMedCentralCrossRef
18.
Zurück zum Zitat Scire CA et al (2013) Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: Results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 15(5):R101 PubMedPubMedCentralCrossRef Scire CA et al (2013) Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: Results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 15(5):R101 PubMedPubMedCentralCrossRef
19.
20.
Zurück zum Zitat Sarawate CA et al (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12(2):61–65 PubMedCrossRef Sarawate CA et al (2006) Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 12(2):61–65 PubMedCrossRef
21.
Zurück zum Zitat Shields GE, Beard SM (2015) A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics 33(10):1029–1047 PubMedCrossRef Shields GE, Beard SM (2015) A systematic review of the economic and humanistic burden of gout. Pharmacoeconomics 33(10):1029–1047 PubMedCrossRef
22.
Zurück zum Zitat Pascual E, Sivera F, Andres M (2011) Synovial fluid analysis for crystals. Curr Opin Rheumatol 23(2):161–169 PubMed Pascual E, Sivera F, Andres M (2011) Synovial fluid analysis for crystals. Curr Opin Rheumatol 23(2):161–169 PubMed
23.
Zurück zum Zitat Khanna D et al (2012) American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431–1446 CrossRef Khanna D et al (2012) American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 64(10):1431–1446 CrossRef
25.
Zurück zum Zitat Zhang W et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1301–1311 PubMedPubMedCentralCrossRef Zhang W et al (2006) EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1301–1311 PubMedPubMedCentralCrossRef
26.
Zurück zum Zitat Schlesinger N, Norquist JM, Watson DJ (2009) Serum urate during acute gout. J Rheumatol 36(6):1287–1289 PubMedCrossRef Schlesinger N, Norquist JM, Watson DJ (2009) Serum urate during acute gout. J Rheumatol 36(6):1287–1289 PubMedCrossRef
27.
Zurück zum Zitat Janssens HJ et al (2010) A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 170(13):1120–1126 PubMedCrossRef Janssens HJ et al (2010) A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 170(13):1120–1126 PubMedCrossRef
28.
Zurück zum Zitat Kienhorst LB et al (2015) The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology (Oxford) 54(4):609–614 CrossRef Kienhorst LB et al (2015) The validation of a diagnostic rule for gout without joint fluid analysis: A prospective study. Rheumatology (Oxford) 54(4):609–614 CrossRef
29.
Zurück zum Zitat Dalbeth N et al (2007) Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 46(12):1804–1807 CrossRef Dalbeth N et al (2007) Tophaceous joint disease strongly predicts hand function in patients with gout. Rheumatology (Oxford) 46(12):1804–1807 CrossRef
30.
Zurück zum Zitat Ogdie A et al (2015) Imaging modalities for the classification of gout: Systematic literature review and meta-analysis. Ann Rheum Dis 74(10):1868–1874 PubMedCrossRef Ogdie A et al (2015) Imaging modalities for the classification of gout: Systematic literature review and meta-analysis. Ann Rheum Dis 74(10):1868–1874 PubMedCrossRef
31.
Zurück zum Zitat Chowalloor PV, Keen HI (2013) A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis 72(5):638–645 PubMedCrossRef Chowalloor PV, Keen HI (2013) A systematic review of ultrasonography in gout and asymptomatic hyperuricaemia. Ann Rheum Dis 72(5):638–645 PubMedCrossRef
32.
Zurück zum Zitat Ottaviani S et al (2012) Ultrasonography in gout: A case-control study. Clin Exp Rheumatol 30(4):499–504 PubMed Ottaviani S et al (2012) Ultrasonography in gout: A case-control study. Clin Exp Rheumatol 30(4):499–504 PubMed
33.
Zurück zum Zitat Naredo E et al (2014) Ultrasound-detected musculoskeletal urate crystal deposition: Which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 73(8):1522–1528 PubMedCrossRef Naredo E et al (2014) Ultrasound-detected musculoskeletal urate crystal deposition: Which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 73(8):1522–1528 PubMedCrossRef
34.
Zurück zum Zitat Choi HK et al (2012) Dual energy CT in gout: A prospective validation study. Ann Rheum Dis 71(9):1466–1471 PubMedCrossRef Choi HK et al (2012) Dual energy CT in gout: A prospective validation study. Ann Rheum Dis 71(9):1466–1471 PubMedCrossRef
35.
Zurück zum Zitat Huppertz A et al (2014) Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int 34(6):763–771 PubMedCrossRef Huppertz A et al (2014) Systemic staging for urate crystal deposits with dual-energy CT and ultrasound in patients with suspected gout. Rheumatol Int 34(6):763–771 PubMedCrossRef
36.
Zurück zum Zitat Bongartz T et al (2015) Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 74(6):1072–1077 PubMedCrossRef Bongartz T et al (2015) Dual-energy CT for the diagnosis of gout: an accuracy and diagnostic yield study. Ann Rheum Dis 74(6):1072–1077 PubMedCrossRef
37.
Zurück zum Zitat Melzer R et al (2014) Gout tophus detection – a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum 43(5):662–665 PubMedCrossRef Melzer R et al (2014) Gout tophus detection – a comparison of dual-energy CT (DECT) and histology. Semin Arthritis Rheum 43(5):662–665 PubMedCrossRef
38.
Zurück zum Zitat Khanna D et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64(10):1447–1461 CrossRef Khanna D et al (2012) American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64(10):1447–1461 CrossRef
39.
Zurück zum Zitat Sriranganathan MK et al (2014) Interventions for tophi in gout: A Cochrane systematic literature review. J Rheumatol Suppl 92:63–69 PubMedCrossRef Sriranganathan MK et al (2014) Interventions for tophi in gout: A Cochrane systematic literature review. J Rheumatol Suppl 92:63–69 PubMedCrossRef
40.
Zurück zum Zitat Khanna PP et al (2014) Treatment of acute gout: A systematic review. Semin Arthritis Rheum 44(1):31–38 PubMedCrossRef Khanna PP et al (2014) Treatment of acute gout: A systematic review. Semin Arthritis Rheum 44(1):31–38 PubMedCrossRef
41.
Zurück zum Zitat van Durme CM et al (2014) Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 9:CD010120 PubMed van Durme CM et al (2014) Non-steroidal anti-inflammatory drugs for acute gout. Cochrane Database Syst Rev 9:CD010120 PubMed
42.
Zurück zum Zitat Rees F, Hui M, Doherty M (2014) Optimizing current treatment of gout. Nat Rev Rheumatol 10(5):271–283 PubMedCrossRef Rees F, Hui M, Doherty M (2014) Optimizing current treatment of gout. Nat Rev Rheumatol 10(5):271–283 PubMedCrossRef
43.
Zurück zum Zitat Altman RD et al (1988) Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study. J Rheumatol 15(9):1422–1426 PubMed Altman RD et al (1988) Ketoprofen versus indomethacin in patients with acute gouty arthritis: A multicenter, double blind comparative study. J Rheumatol 15(9):1422–1426 PubMed
44.
45.
Zurück zum Zitat Maccagno A, Di Giorgio E, Romanowicz A (1991) Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin 12(7):423–429 PubMedCrossRef Maccagno A, Di Giorgio E, Romanowicz A (1991) Effectiveness of etodolac (‘Lodine’) compared with naproxen in patients with acute gout. Curr Med Res Opin 12(7):423–429 PubMedCrossRef
46.
Zurück zum Zitat Rubin BR et al (2004) Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum 50(2):598–606 PubMedCrossRef Rubin BR et al (2004) Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: A randomized controlled trial. Arthritis Rheum 50(2):598–606 PubMedCrossRef
47.
Zurück zum Zitat Reardon JA et al (1980) Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 6(7):445–448 PubMedCrossRef Reardon JA et al (1980) Double-blind trial of feprazone and phenylbutazone in acute gout. Curr Med Res Opin 6(7):445–448 PubMedCrossRef
48.
Zurück zum Zitat Janssens HJ et al (2008) Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 371(9627):1854–1860 PubMedCrossRef Janssens HJ et al (2008) Use of oral prednisolone or naproxen for the treatment of gout arthritis: A double-blind, randomised equivalence trial. Lancet 371(9627):1854–1860 PubMedCrossRef
49.
Zurück zum Zitat Li T et al (2013) Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: A randomized double-blind trial. Chin Med J (Engl) 126(10):1867–1871 Li T et al (2013) Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: A randomized double-blind trial. Chin Med J (Engl) 126(10):1867–1871
50.
Zurück zum Zitat Schumacher HR et al (2012) Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: A randomized controlled trial. J Rheumatol 39(9):1859–1866 PubMedCrossRef Schumacher HR et al (2012) Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: A randomized controlled trial. J Rheumatol 39(9):1859–1866 PubMedCrossRef
52.
Zurück zum Zitat Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068 PubMedCrossRef Terkeltaub RA et al (2010) High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum 62(4):1060–1068 PubMedCrossRef
53.
Zurück zum Zitat van Echteld I et al (2014) Colchicine for acute gout. Cochrane Database Syst Rev 8:CD006190 PubMed van Echteld I et al (2014) Colchicine for acute gout. Cochrane Database Syst Rev 8:CD006190 PubMed
54.
Zurück zum Zitat Schlesinger N et al (2002) Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 29(2):331–334 PubMed Schlesinger N et al (2002) Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 29(2):331–334 PubMed
55.
Zurück zum Zitat Ahern MJ et al (1987) Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17(3):301–304 PubMedCrossRef Ahern MJ et al (1987) Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 17(3):301–304 PubMedCrossRef
56.
Zurück zum Zitat Janssens HJ et al (2008) Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2:CD005521 PubMed Janssens HJ et al (2008) Systemic corticosteroids for acute gout. Cochrane Database Syst Rev 2:CD005521 PubMed
57.
Zurück zum Zitat Wechalekar MD et al (2013) Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 4:CD009920 PubMed Wechalekar MD et al (2013) Intra-articular glucocorticoids for acute gout. Cochrane Database Syst Rev 4:CD009920 PubMed
58.
Zurück zum Zitat Fernandez C et al (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26(10):2285–2286 PubMed Fernandez C et al (1999) Treatment of acute attacks of gout with a small dose of intraarticular triamcinolone acetonide. J Rheumatol 26(10):2285–2286 PubMed
59.
Zurück zum Zitat Komatsu T (1969) Treatment of acute gouty attack with local infiltration of Kenacort – A and the study of gout and hyperuricemia at the Tanabe National Hospital during 1967. Iryo 23(1):54–61 PubMed Komatsu T (1969) Treatment of acute gouty attack with local infiltration of Kenacort – A and the study of gout and hyperuricemia at the Tanabe National Hospital during 1967. Iryo 23(1):54–61 PubMed
60.
Zurück zum Zitat Schlesinger N et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71(11):1839–1848 PubMedCrossRef Schlesinger N et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: Results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71(11):1839–1848 PubMedCrossRef
61.
Zurück zum Zitat Schlesinger N et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53 PubMedPubMedCentralCrossRef Schlesinger N et al (2011) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: Results of a randomized, dose-ranging study. Arthritis Res Ther 13(2):R53 PubMedPubMedCentralCrossRef
62.
Zurück zum Zitat So A et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064–3076 PubMedCrossRef So A et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: Results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62(10):3064–3076 PubMedCrossRef
63.
Zurück zum Zitat Schlesinger N et al (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study. Ann Rheum Dis 70(7):1264–1271 PubMedPubMedCentralCrossRef Schlesinger N et al (2011) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: Results of a double-blind, randomised study. Ann Rheum Dis 70(7):1264–1271 PubMedPubMedCentralCrossRef
64.
Zurück zum Zitat Mitha E et al (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: Results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 52(7):1285–1292 CrossRef Mitha E et al (2013) Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: Results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology (Oxford) 52(7):1285–1292 CrossRef
65.
Zurück zum Zitat Schumacher HR Jr. et al (2012) Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 64(3):876–884 PubMedCrossRef Schumacher HR Jr. et al (2012) Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: Results of a phase II randomized, double-blind, placebo-controlled trial. Arthritis Rheum 64(3):876–884 PubMedCrossRef
66.
Zurück zum Zitat Terkeltaub RA et al (2013) Rilonacept in the treatment of acute gouty arthritis: A randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 15(1):R25 PubMedPubMedCentralCrossRef Terkeltaub RA et al (2013) Rilonacept in the treatment of acute gouty arthritis: A randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 15(1):R25 PubMedPubMedCentralCrossRef
67.
Zurück zum Zitat Schumacher HR Jr. et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 64(10):1462–1470 CrossRef Schumacher HR Jr. et al (2012) Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: Results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study. Arthritis Care Res (Hoboken) 64(10):1462–1470 CrossRef
69.
Zurück zum Zitat Thueringer JT, Doll NK, Gertner E (2015) Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum 45(1):81–85 PubMedCrossRef Thueringer JT, Doll NK, Gertner E (2015) Anakinra for the treatment of acute severe gout in critically ill patients. Semin Arthritis Rheum 45(1):81–85 PubMedCrossRef
70.
Zurück zum Zitat Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14(3):e33–7 PubMedCrossRef Tran AP, Edelman J (2011) Interleukin-1 inhibition by anakinra in refractory chronic tophaceous gout. Int J Rheum Dis 14(3):e33–7 PubMedCrossRef
71.
Zurück zum Zitat Richette P et al (2014) Updated Eular evidence-based recommendations for gout. Part II: management. Ann Rheum Dis 2014;73(Suppl2):783 Richette P et al (2014) Updated Eular evidence-based recommendations for gout. Part II: management. Ann Rheum Dis 2014;73(Suppl2):783
72.
Zurück zum Zitat Taylor TH et al (2012) Initiation of allopurinol at first medical contact for acute attacks of gout: A randomized clinical trial. Am J Med 125(11):1126–1134.e7 PubMedCrossRef Taylor TH et al (2012) Initiation of allopurinol at first medical contact for acute attacks of gout: A randomized clinical trial. Am J Med 125(11):1126–1134.e7 PubMedCrossRef
73.
Zurück zum Zitat Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51(3):321–325 PubMedCrossRef Shoji A, Yamanaka H, Kamatani N (2004) A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: Evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 51(3):321–325 PubMedCrossRef
74.
Zurück zum Zitat Pascual E, Sivera F (2007) Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 66(8):1056–1058 PubMedPubMedCentralCrossRef Pascual E, Sivera F (2007) Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 66(8):1056–1058 PubMedPubMedCentralCrossRef
75.
Zurück zum Zitat Perez-Ruiz F et al (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47(4):356–360 PubMedCrossRef Perez-Ruiz F et al (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47(4):356–360 PubMedCrossRef
76.
Zurück zum Zitat Andres M et al (2014) Treatment target and followup measures for patients with gout: A systematic literature review. J Rheumatol Suppl 92:55–62 PubMedCrossRef Andres M et al (2014) Treatment target and followup measures for patients with gout: A systematic literature review. J Rheumatol Suppl 92:55–62 PubMedCrossRef
77.
Zurück zum Zitat Rees F, Jenkins W, Doherty M (2013) Patients with gout adhere to curative treatment if informed appropriately: Proof-of-concept observational study. Ann Rheum Dis 72(6):826–830 PubMedCrossRef Rees F, Jenkins W, Doherty M (2013) Patients with gout adhere to curative treatment if informed appropriately: Proof-of-concept observational study. Ann Rheum Dis 72(6):826–830 PubMedCrossRef
78.
Zurück zum Zitat Kuo CF et al (2014) Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 312(24):2684–2686 PubMedCrossRef Kuo CF et al (2014) Eligibility for and prescription of urate-lowering treatment in patients with incident gout in England. JAMA 312(24):2684–2686 PubMedCrossRef
79.
Zurück zum Zitat Briesacher BA et al (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28(4):437–443 PubMedPubMedCentralCrossRef Briesacher BA et al (2008) Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 28(4):437–443 PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Perez-Ruiz F, Herrero-Beites AM, Carmona L (2011) A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesis. Arthritis Rheum 63(12):4002–4006 PubMedCrossRef Perez-Ruiz F, Herrero-Beites AM, Carmona L (2011) A two-stage approach to the treatment of hyperuricemia in gout: The “dirty dish” hypothesis. Arthritis Rheum 63(12):4002–4006 PubMedCrossRef
82.
Zurück zum Zitat Tausche AK et al (2014) As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 34(1):101–109 PubMedCrossRef Tausche AK et al (2014) As compared to allopurinol, urate-lowering therapy with febuxostat has superior effects on oxidative stress and pulse wave velocity in patients with severe chronic tophaceous gout. Rheumatol Int 34(1):101–109 PubMedCrossRef
83.
Zurück zum Zitat Seth R et al (2014) Allopurinol for chronic gout. Cochrane Database Syst Rev 10:CD006077 PubMed Seth R et al (2014) Allopurinol for chronic gout. Cochrane Database Syst Rev 10:CD006077 PubMed
84.
Zurück zum Zitat Stamp LK et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529–2536 PubMedCrossRef Stamp LK et al (2012) Starting dose is a risk factor for allopurinol hypersensitivity syndrome: A proposed safe starting dose of allopurinol. Arthritis Rheum 64(8):2529–2536 PubMedCrossRef
85.
Zurück zum Zitat Stamp LK et al (2014) Impaired response or insufficient dosage? Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Semin Arthritis Rheum 44(2):170–174 PubMedPubMedCentralCrossRef Stamp LK et al (2014) Impaired response or insufficient dosage? Examining the potential causes of “inadequate response” to allopurinol in the treatment of gout. Semin Arthritis Rheum 44(2):170–174 PubMedPubMedCentralCrossRef
86.
Zurück zum Zitat Stamp LK et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412–421 PubMedCrossRef Stamp LK et al (2011) Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 63(2):412–421 PubMedCrossRef
87.
Zurück zum Zitat Ramasamy SN et al (2013) Allopurinol hypersensitivity: A systematic review of all published cases, 1950–2012. Drug Saf 36(10):953–980 PubMedCrossRef Ramasamy SN et al (2013) Allopurinol hypersensitivity: A systematic review of all published cases, 1950–2012. Drug Saf 36(10):953–980 PubMedCrossRef
88.
Zurück zum Zitat Kim SC et al (2013) Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res (Hoboken) 65(4):578–584 CrossRef Kim SC et al (2013) Severe cutaneous reactions requiring hospitalization in allopurinol initiators: A population-based cohort study. Arthritis Care Res (Hoboken) 65(4):578–584 CrossRef
89.
Zurück zum Zitat Halevy S et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25–32 PubMedCrossRef Halevy S et al (2008) Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 58(1):25–32 PubMedCrossRef
90.
Zurück zum Zitat Hershfield MS et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 93(2):153–158 PubMedCrossRef Hershfield MS et al (2013) Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. Clin Pharmacol Ther 93(2):153–158 PubMedCrossRef
91.
Zurück zum Zitat Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461 PubMedCrossRef Becker MA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461 PubMedCrossRef
92.
Zurück zum Zitat Schumacher HR Jr. et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540–1548 PubMedCrossRef Schumacher HR Jr. et al (2008) Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: A 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 59(11):1540–1548 PubMedCrossRef
93.
Zurück zum Zitat Becker MA et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 12(2):R63 PubMedPubMedCentralCrossRef Becker MA et al (2010) The urate-lowering efficacy and safety of febuxostat in the treatment of the hyperuricemia of gout: The CONFIRMS trial. Arthritis Res Ther 12(2):R63 PubMedPubMedCentralCrossRef
95.
Zurück zum Zitat Chohan S (2011) Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 38(9):1957–1959 PubMedCrossRef Chohan S (2011) Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions. J Rheumatol 38(9):1957–1959 PubMedCrossRef
96.
Zurück zum Zitat Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database Syst Rev 11:CD008653 PubMedPubMedCentral Tayar JH, Lopez-Olivo MA, Suarez-Almazor ME (2012) Febuxostat for treating chronic gout. Cochrane Database Syst Rev 11:CD008653 PubMedPubMedCentral
97.
Zurück zum Zitat Ye P et al (2013) Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: A systematic review and meta-analysis. Clin Ther 35(2):180–189 PubMedCrossRef Ye P et al (2013) Efficacy and tolerability of febuxostat in hyperuricemic patients with or without gout: A systematic review and meta-analysis. Clin Ther 35(2):180–189 PubMedCrossRef
98.
Zurück zum Zitat Grewal HK, Martinez JR, Espinoza LR (2014) Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol 10(5):747–758 PubMedCrossRef Grewal HK, Martinez JR, Espinoza LR (2014) Febuxostat: drug review and update. Expert Opin Drug Metab Toxicol 10(5):747–758 PubMedCrossRef
99.
Zurück zum Zitat Jansen TL et al (2010) International position paper on febuxostat. Clin Rheumatol 29(8):835–840 PubMedCrossRef Jansen TL et al (2010) International position paper on febuxostat. Clin Rheumatol 29(8):835–840 PubMedCrossRef
100.
Zurück zum Zitat Faruque LI et al (2013) A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43(3):367–375 PubMedCrossRef Faruque LI et al (2013) A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout. Semin Arthritis Rheum 43(3):367–375 PubMedCrossRef
101.
102.
Zurück zum Zitat Reinders MK et al (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 68(6):892–897 PubMedCrossRef Reinders MK et al (2009) A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout. Ann Rheum Dis 68(6):892–897 PubMedCrossRef
103.
Zurück zum Zitat Kydd AS et al (2014) Uricosuric medications for chronic gout. Cochrane Database Syst Rev 11:CD010457 PubMed Kydd AS et al (2014) Uricosuric medications for chronic gout. Cochrane Database Syst Rev 11:CD010457 PubMed
104.
Zurück zum Zitat Okuda C et al (2011) Serum CRP in patients with gout and effects of benzbromarone. Int J Clin Pharmacol Ther 49(3):191–197 PubMedCrossRef Okuda C et al (2011) Serum CRP in patients with gout and effects of benzbromarone. Int J Clin Pharmacol Ther 49(3):191–197 PubMedCrossRef
105.
Zurück zum Zitat Johnson RJ et al (2005) Uric acid, evolution and primitive cultures. Semin Nephrol 25(1):3–8 PubMedCrossRef Johnson RJ et al (2005) Uric acid, evolution and primitive cultures. Semin Nephrol 25(1):3–8 PubMedCrossRef
106.
Zurück zum Zitat Anderson A, Singh JA (2010) Pegloticase for chronic gout. Cochrane Database Syst Rev 3:CD008335 PubMed Anderson A, Singh JA (2010) Pegloticase for chronic gout. Cochrane Database Syst Rev 3:CD008335 PubMed
107.
Zurück zum Zitat Strand V et al (2012) Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials. J Rheumatol 39(7):1450–1457 PubMedCrossRef Strand V et al (2012) Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: Evidence from phase III randomized controlled trials. J Rheumatol 39(7):1450–1457 PubMedCrossRef
108.
Zurück zum Zitat Sundy JS et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 306(7):711–720 PubMedCrossRef Sundy JS et al (2011) Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: Two randomized controlled trials. JAMA 306(7):711–720 PubMedCrossRef
109.
Zurück zum Zitat Lee YH, Lee CH, Lee J (2006) Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med 21(2):89–93 PubMedPubMedCentralCrossRef Lee YH, Lee CH, Lee J (2006) Effect of fenofibrate in combination with urate lowering agents in patients with gout. Korean J Intern Med 21(2):89–93 PubMedPubMedCentralCrossRef
110.
Zurück zum Zitat Saar J, Kirch W (2014) A new application for well-known pharmaceutics – losartan and fenofibrate as potential remedies against gout? Dtsch Med Wochenschr 139(12):608 PubMedCrossRef Saar J, Kirch W (2014) A new application for well-known pharmaceutics – losartan and fenofibrate as potential remedies against gout? Dtsch Med Wochenschr 139(12):608 PubMedCrossRef
111.
Zurück zum Zitat Hosoya T et al (2012) Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med 51(18):2509–2514 PubMedCrossRef Hosoya T et al (2012) Effects of combined antihypertensive therapy with losartan/hydrochlorothiazide on uric acid metabolism. Intern Med 51(18):2509–2514 PubMedCrossRef
112.
Zurück zum Zitat Miao Y et al (2011) Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58(1):2–7 PubMedCrossRef Miao Y et al (2011) Effect of a reduction in uric acid on renal outcomes during losartan treatment: A post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the Angiotensin II Antagonist Losartan Trial. Hypertension 58(1):2–7 PubMedCrossRef
113.
Zurück zum Zitat McGill NW (2000) Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 14(3):445–460 PubMedCrossRef McGill NW (2000) Gout and other crystal-associated arthropathies. Baillieres Best Pract Res Clin Rheumatol 14(3):445–460 PubMedCrossRef
114.
Zurück zum Zitat Rothenbacher D et al (2011) Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 50(5):973–981 CrossRef Rothenbacher D et al (2011) Frequency and risk factors of gout flares in a large population-based cohort of incident gout. Rheumatology (Oxford) 50(5):973–981 CrossRef
115.
Zurück zum Zitat Wortmann RL et al (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397 PubMedCrossRef Wortmann RL et al (2010) Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. Clin Ther 32(14):2386–2397 PubMedCrossRef
116.
Zurück zum Zitat Dalbeth N et al (2014) Zoledronate for prevention of bone erosion in tophaceous gout: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 73(6):1044–1051 PubMedCrossRef Dalbeth N et al (2014) Zoledronate for prevention of bone erosion in tophaceous gout: A randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 73(6):1044–1051 PubMedCrossRef
117.
Zurück zum Zitat Becker MA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36(6):1273–1282 PubMedCrossRef Becker MA et al (2009) Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol 36(6):1273–1282 PubMedCrossRef
118.
Zurück zum Zitat Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40(1):37–42 PubMedCrossRef Kramer HM, Curhan G (2002) The association between gout and nephrolithiasis: The National Health and Nutrition Examination Survey III, 1988–1994. Am J Kidney Dis 40(1):37–42 PubMedCrossRef
120.
Zurück zum Zitat Krishnan E (2013) Chronic kidney disease and the risk of incident gout among middle-aged men: A seven-year prospective observational study. Arthritis Rheum 65(12):3271–3278 PubMedCrossRef Krishnan E (2013) Chronic kidney disease and the risk of incident gout among middle-aged men: A seven-year prospective observational study. Arthritis Rheum 65(12):3271–3278 PubMedCrossRef
121.
Zurück zum Zitat Jalal DI et al (2013) Uric acid as a target of therapy in CKD. Am J Kidney Dis 61(1):134–146 PubMedCrossRef Jalal DI et al (2013) Uric acid as a target of therapy in CKD. Am J Kidney Dis 61(1):134–146 PubMedCrossRef
122.
Zurück zum Zitat Liu WC et al (2012) Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 7(4):541–548 PubMedCrossRef Liu WC et al (2012) Association of hyperuricemia with renal outcomes, cardiovascular disease, and mortality. Clin J Am Soc Nephrol 7(4):541–548 PubMedCrossRef
123.
Zurück zum Zitat Chang HY et al (2010) Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 339(6):509–515 PubMedCrossRef Chang HY et al (2010) Hyperuricemia as an independent risk factor of chronic kidney disease in middle-aged and elderly population. Am J Med Sci 339(6):509–515 PubMedCrossRef
125.
Zurück zum Zitat Whelton A et al (2011) Renal function in gout: Long-term treatment effects of febuxostat. J Clin Rheumatol 17(1):7–13 PubMedCrossRef Whelton A et al (2011) Renal function in gout: Long-term treatment effects of febuxostat. J Clin Rheumatol 17(1):7–13 PubMedCrossRef
126.
Zurück zum Zitat Sedaghat S et al (2013) Serum uric acid and chronic kidney disease: The role of hypertension. PLoS ONE 8(e76827):11 Sedaghat S et al (2013) Serum uric acid and chronic kidney disease: The role of hypertension. PLoS ONE 8(e76827):11
127.
Zurück zum Zitat Chang HY et al (2013) Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: A prospective cohort study in taiwan. PLoS ONE 8(4):e61450 PubMedPubMedCentralCrossRef Chang HY et al (2013) Hyperuricemia is an independent risk factor for new onset micro-albuminuria in a middle-aged and elderly population: A prospective cohort study in taiwan. PLoS ONE 8(4):e61450 PubMedPubMedCentralCrossRef
128.
Zurück zum Zitat Levy GD et al (2014) Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol 41(5):955–962 PubMedCrossRef Levy GD et al (2014) Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia. J Rheumatol 41(5):955–962 PubMedCrossRef
129.
Zurück zum Zitat Siu YP et al (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51–59 PubMedCrossRef Siu YP et al (2006) Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis 47(1):51–59 PubMedCrossRef
130.
Zurück zum Zitat Goicoechea M et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393 PubMedPubMedCentralCrossRef Goicoechea M et al (2010) Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 5(8):1388–1393 PubMedPubMedCentralCrossRef
132.
Zurück zum Zitat Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 300(8):924–932 PubMedPubMedCentralCrossRef Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 300(8):924–932 PubMedPubMedCentralCrossRef
133.
Zurück zum Zitat Zhang W et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324 PubMedPubMedCentralCrossRef Zhang W et al (2006) EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65(10):1312–1324 PubMedPubMedCentralCrossRef
134.
Zurück zum Zitat Choi HK et al (2004) Alcohol intake and risk of incident gout in men: A prospective study. Lancet 363(9417):1277–1281 PubMedCrossRef Choi HK et al (2004) Alcohol intake and risk of incident gout in men: A prospective study. Lancet 363(9417):1277–1281 PubMedCrossRef
135.
Zurück zum Zitat Dalbeth N, Gow P (2006) Alcohol excess may be overemphasised in gout treated in secondary care. N Z Med J 119(1243):U2270 PubMed Dalbeth N, Gow P (2006) Alcohol excess may be overemphasised in gout treated in secondary care. N Z Med J 119(1243):U2270 PubMed
136.
Zurück zum Zitat Choi JW et al (2008) Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 59(1):109–116 PubMedCrossRef Choi JW et al (2008) Sugar-sweetened soft drinks, diet soft drinks, and serum uric acid level: The Third National Health and Nutrition Examination Survey. Arthritis Rheum 59(1):109–116 PubMedCrossRef
137.
Zurück zum Zitat Choi HK et al (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med 165(7):742–748 PubMedCrossRef Choi HK et al (2005) Obesity, weight change, hypertension, diuretic use, and risk of gout in men: The health professionals follow-up study. Arch Intern Med 165(7):742–748 PubMedCrossRef
138.
Zurück zum Zitat Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol 23(2):192–202 PubMedPubMedCentral Singh JA, Reddy SG, Kundukulam J (2011) Risk factors for gout and prevention: A systematic review of the literature. Curr Opin Rheumatol 23(2):192–202 PubMedPubMedCentral
139.
Zurück zum Zitat Wang M et al (2013) A meta-analysis of alcohol consumption and the risk of gout. Clin Rheumatol 32(11):1641–1648 PubMedCrossRef Wang M et al (2013) A meta-analysis of alcohol consumption and the risk of gout. Clin Rheumatol 32(11):1641–1648 PubMedCrossRef
140.
Zurück zum Zitat Andres M et al (2014) Dietary supplements for chronic gout. Cochrane Database Syst Rev 10:CD010156 PubMed Andres M et al (2014) Dietary supplements for chronic gout. Cochrane Database Syst Rev 10:CD010156 PubMed
141.
Zurück zum Zitat Moi JH et al (2013) Lifestyle interventions for chronic gout. Cochrane Database Syst Rev 5:CD010039 PubMed Moi JH et al (2013) Lifestyle interventions for chronic gout. Cochrane Database Syst Rev 5:CD010039 PubMed
142.
Zurück zum Zitat Stamp LK et al (2013) Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: A pilot randomized controlled trial. Arthritis Rheum 65(6):1636–1642 PubMedCrossRef Stamp LK et al (2013) Clinically insignificant effect of supplemental vitamin C on serum urate in patients with gout: A pilot randomized controlled trial. Arthritis Rheum 65(6):1636–1642 PubMedCrossRef
143.
Zurück zum Zitat Dalbeth N et al (2012) Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: A proof-of-concept randomised controlled trial. Ann Rheum Dis 71(6):929–934 PubMedCrossRef Dalbeth N et al (2012) Effects of skim milk powder enriched with glycomacropeptide and G600 milk fat extract on frequency of gout flares: A proof-of-concept randomised controlled trial. Ann Rheum Dis 71(6):929–934 PubMedCrossRef
144.
Zurück zum Zitat Wang W, Krishnan E (2015) Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford) 54(1):91–95 CrossRef Wang W, Krishnan E (2015) Cigarette smoking is associated with a reduction in the risk of incident gout: results from the Framingham Heart Study original cohort. Rheumatology (Oxford) 54(1):91–95 CrossRef
145.
Zurück zum Zitat Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116(8):894–900 PubMedCrossRef Choi HK, Curhan G (2007) Independent impact of gout on mortality and risk for coronary heart disease. Circulation 116(8):894–900 PubMedCrossRef
146.
Zurück zum Zitat Riedel AA et al (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10(6):308–314 PubMedCrossRef Riedel AA et al (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10(6):308–314 PubMedCrossRef
148.
149.
Zurück zum Zitat Kuo CF et al (2012) Increased risk of cancer among gout patients: A nationwide population study. Joint Bone Spine 79(4):375–378 PubMedCrossRef Kuo CF et al (2012) Increased risk of cancer among gout patients: A nationwide population study. Joint Bone Spine 79(4):375–378 PubMedCrossRef
150.
Zurück zum Zitat Savarese G et al (2013) Changes in serum uric acid levels and cardiovascular events: A meta-analysis. Nutr Metab Cardiovasc Dis 23(8):707–714 PubMedCrossRef Savarese G et al (2013) Changes in serum uric acid levels and cardiovascular events: A meta-analysis. Nutr Metab Cardiovasc Dis 23(8):707–714 PubMedCrossRef
151.
Zurück zum Zitat Lottmann K, Chen X, Schadlich PK (2012) Association between gout and all-cause as well as cardiovascular mortality: A systematic review. Curr Rheumatol Rep 14(2):195–203 PubMedPubMedCentralCrossRef Lottmann K, Chen X, Schadlich PK (2012) Association between gout and all-cause as well as cardiovascular mortality: A systematic review. Curr Rheumatol Rep 14(2):195–203 PubMedPubMedCentralCrossRef
152.
Zurück zum Zitat Dutta A et al (2013) Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc 61(3):319–326 PubMedCrossRef Dutta A et al (2013) Uric acid measurement improves prediction of cardiovascular mortality in later life. J Am Geriatr Soc 61(3):319–326 PubMedCrossRef
153.
Zurück zum Zitat Stack AG et al (2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106(7):647–658 PubMedCrossRef Stack AG et al (2013) Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. QJM 106(7):647–658 PubMedCrossRef
154.
Zurück zum Zitat Kuo CF et al (2010) Gout: An independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 49(1):141–146 CrossRef Kuo CF et al (2010) Gout: An independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 49(1):141–146 CrossRef
155.
Zurück zum Zitat Teng GG et al (2012) Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 71(6):924–928 PubMedCrossRef Teng GG et al (2012) Mortality due to coronary heart disease and kidney disease among middle-aged and elderly men and women with gout in the Singapore Chinese Health Study. Ann Rheum Dis 71(6):924–928 PubMedCrossRef
156.
Zurück zum Zitat Krishnan E et al (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis – data from a prospective observational cohort study. Arthritis Res Ther 13(2):R66 PubMedPubMedCentralCrossRef Krishnan E et al (2011) Hyperuricemia and the risk for subclinical coronary atherosclerosis – data from a prospective observational cohort study. Arthritis Res Ther 13(2):R66 PubMedPubMedCentralCrossRef
157.
Zurück zum Zitat Kim SY et al (2010) Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62(2):170–180 Kim SY et al (2010) Hyperuricemia and coronary heart disease: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 62(2):170–180
158.
Zurück zum Zitat Trkulja V, Car S (2012) On-admission serum uric acid predicts outcomes after acute myocardial infarction: Systematic review and meta-analysis of prognostic studies. Croat Med J 53(2):162–172 PubMedPubMedCentralCrossRef Trkulja V, Car S (2012) On-admission serum uric acid predicts outcomes after acute myocardial infarction: Systematic review and meta-analysis of prognostic studies. Croat Med J 53(2):162–172 PubMedPubMedCentralCrossRef
159.
Zurück zum Zitat De Vera MA et al (2010) Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis 69(6):1162–1164 PubMedPubMedCentralCrossRef De Vera MA et al (2010) Independent impact of gout on the risk of acute myocardial infarction among elderly women: A population-based study. Ann Rheum Dis 69(6):1162–1164 PubMedPubMedCentralCrossRef
160.
Zurück zum Zitat Li M et al (2014) Hyperuricemia and risk of stroke: A systematic review and meta-analysis of prospective studies. Atherosclerosis 232(2):265–270 PubMedCrossRef Li M et al (2014) Hyperuricemia and risk of stroke: A systematic review and meta-analysis of prospective studies. Atherosclerosis 232(2):265–270 PubMedCrossRef
161.
Zurück zum Zitat Nyrnes A et al (2014) Uric acid is associated with future atrial fibrillation: An 11-year follow-up of 6308 men and women – the Tromso Study. Europace 16(3):320–326 PubMedCrossRef Nyrnes A et al (2014) Uric acid is associated with future atrial fibrillation: An 11-year follow-up of 6308 men and women – the Tromso Study. Europace 16(3):320–326 PubMedCrossRef
162.
Zurück zum Zitat Grayson PC et al (2011) Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(1):102–110 CrossRef Grayson PC et al (2011) Hyperuricemia and incident hypertension: A systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63(1):102–110 CrossRef
163.
Zurück zum Zitat Huang H et al (2014) Uric acid and risk of heart failure: A systematic review and meta-analysis. Eur J Heart Fail 16(1):15–24 PubMedCrossRef Huang H et al (2014) Uric acid and risk of heart failure: A systematic review and meta-analysis. Eur J Heart Fail 16(1):15–24 PubMedCrossRef
164.
Zurück zum Zitat Tamariz L et al (2011) Uric acid as a predictor of all-cause mortality in heart failure: A meta-analysis. Congest Heart Fail 17(1):25–30 PubMedCrossRef Tamariz L et al (2011) Uric acid as a predictor of all-cause mortality in heart failure: A meta-analysis. Congest Heart Fail 17(1):25–30 PubMedCrossRef
165.
Zurück zum Zitat Wu AH et al (2010) Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 160(5):928–933 PubMedCrossRef Wu AH et al (2010) Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. Am Heart J 160(5):928–933 PubMedCrossRef
167.
Zurück zum Zitat Hamaguchi S et al (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151(2):143–147 PubMedCrossRef Hamaguchi S et al (2011) Hyperuricemia predicts adverse outcomes in patients with heart failure. Int J Cardiol 151(2):143–147 PubMedCrossRef
168.
Zurück zum Zitat Hueskes BA et al (2012) A case–control study of determinants for the occurrence of gouty arthritis in heart failure patients. Eur J Heart Fail 14(8):916–921 PubMedCrossRef Hueskes BA et al (2012) A case–control study of determinants for the occurrence of gouty arthritis in heart failure patients. Eur J Heart Fail 14(8):916–921 PubMedCrossRef
169.
Zurück zum Zitat Jia Z et al (2013) Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: A meta-analysis of cohort studies. Diabetes Res Clin Pract 101(1):88–96 PubMedCrossRef Jia Z et al (2013) Serum uric acid levels and incidence of impaired fasting glucose and type 2 diabetes mellitus: A meta-analysis of cohort studies. Diabetes Res Clin Pract 101(1):88–96 PubMedCrossRef
170.
Zurück zum Zitat Xu Y et al (2013) Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: A meta-analysis. PLoS ONE 8(10):e78206 PubMedPubMedCentralCrossRef Xu Y et al (2013) Hyperuricemia as an independent predictor of vascular complications and mortality in type 2 diabetes patients: A meta-analysis. PLoS ONE 8(10):e78206 PubMedPubMedCentralCrossRef
171.
Zurück zum Zitat Lv Q et al (2013) High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. PLoS ONE 8(2):e56864 PubMedPubMedCentralCrossRef Lv Q et al (2013) High serum uric acid and increased risk of type 2 diabetes: A systemic review and meta-analysis of prospective cohort studies. PLoS ONE 8(2):e56864 PubMedPubMedCentralCrossRef
173.
Zurück zum Zitat Rodriguez G, Soriano LC, Choi HK (2010) Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 69(12):2090–2094 PubMedCrossRef Rodriguez G, Soriano LC, Choi HK (2010) Impact of diabetes against the future risk of developing gout. Ann Rheum Dis 69(12):2090–2094 PubMedCrossRef
174.
Zurück zum Zitat Chen JH et al (2013) Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 65(1):133–140 CrossRef Chen JH et al (2013) Impact of obesity and hypertriglyceridemia on gout development with or without hyperuricemia: a prospective study. Arthritis Care Res (Hoboken) 65(1):133–140 CrossRef
175.
Zurück zum Zitat Hueskes BA et al (2012) Use of diuretics and the risk of gouty arthritis: A systematic review. Semin Arthritis Rheum 41(6):879–889 PubMedCrossRef Hueskes BA et al (2012) Use of diuretics and the risk of gouty arthritis: A systematic review. Semin Arthritis Rheum 41(6):879–889 PubMedCrossRef
176.
Zurück zum Zitat McAdams-DeMarco MA et al (2012) Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study. Arthritis Rheum 64(1):121–129 PubMedPubMedCentralCrossRef McAdams-DeMarco MA et al (2012) Diuretic use, increased serum urate levels, and risk of incident gout in a population-based study of adults with hypertension: The Atherosclerosis Risk in Communities cohort study. Arthritis Rheum 64(1):121–129 PubMedPubMedCentralCrossRef
177.
Zurück zum Zitat Zhang Y et al (2014) Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 73(2):385–390 PubMedCrossRef Zhang Y et al (2014) Low-dose aspirin use and recurrent gout attacks. Ann Rheum Dis 73(2):385–390 PubMedCrossRef
178.
Zurück zum Zitat Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis 71(9):1490–1495 PubMedCrossRef Spencer K, Carr A, Doherty M (2012) Patient and provider barriers to effective management of gout in general practice: A qualitative study. Ann Rheum Dis 71(9):1490–1495 PubMedCrossRef
179.
Zurück zum Zitat Solomon DH et al (2008) Uric acid lowering therapy: Prescribing patterns in a large cohort of older adults. Ann Rheum Dis 67(5):609–613 PubMedCrossRef Solomon DH et al (2008) Uric acid lowering therapy: Prescribing patterns in a large cohort of older adults. Ann Rheum Dis 67(5):609–613 PubMedCrossRef
180.
181.
Zurück zum Zitat Rashid N et al (2015) Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol 42(3):504–512 PubMedCrossRef Rashid N et al (2015) Modifiable factors associated with allopurinol adherence and outcomes among patients with gout in an integrated healthcare system. J Rheumatol 42(3):504–512 PubMedCrossRef
182.
Zurück zum Zitat Sarawate CA et al (2006) Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81(7):925–934 PubMedCrossRef Sarawate CA et al (2006) Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 81(7):925–934 PubMedCrossRef
183.
Zurück zum Zitat Dalbeth N et al (2012) Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. Bmc Musculoskelet Disord 13:174 PubMedPubMedCentralCrossRef Dalbeth N et al (2012) Prescription and dosing of urate-lowering therapy, rather than patient behaviours, are the key modifiable factors associated with targeting serum urate in gout. Bmc Musculoskelet Disord 13:174 PubMedPubMedCentralCrossRef
184.
Zurück zum Zitat Roddy E et al (2010) Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 49(1):105–111 CrossRef Roddy E et al (2010) Prescription and comorbidity screening following consultation for acute gout in primary care. Rheumatology (Oxford) 49(1):105–111 CrossRef
185.
Zurück zum Zitat Kuo CF et al (2013) Risk of myocardial infarction among patients with gout: A nationwide population-based study. Rheumatology (Oxford) 52(1):111–117 CrossRef Kuo CF et al (2013) Risk of myocardial infarction among patients with gout: A nationwide population-based study. Rheumatology (Oxford) 52(1):111–117 CrossRef
186.
Zurück zum Zitat Neogi T et al (2015) Ann Rheum Dis / Arthritis Rheumatol 67(10):2557–2568 CrossRef Neogi T et al (2015) Ann Rheum Dis / Arthritis Rheumatol 67(10):2557–2568 CrossRef
Metadaten
Titel
Langfassung zur S2e-Leitlinie Gichtarthritis (fachärztlich)
Evidenzbasierte Leitlinie der Deutschen Gesellschaft für Rheumatologie (DGRh)
verfasst von
Dr. med. U. Kiltz
Dr. med. R. Alten
Prof. Dr. med. M. Fleck
Prof. Dr. K. Krüger
Prof. Dr. med. B. Manger
Prof. Dr. med. U. Müller-Ladner
Prof. Dr. med. H. Nüßlein
Prof. Dr. med. M. Reuss-Borst
Prof. Dr. med. A. Schwarting
Prof. Dr. med. H. Schulze-Koops
Dr. med. A. Tausche
Prof. Dr. med. J. Braun
Publikationsdatum
01.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Zeitschrift für Rheumatologie / Ausgabe Sonderheft 2/2016
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI
https://doi.org/10.1007/s00393-016-0147-6

Neu im Fachgebiet Innere Medizin

Update Innere Medizin

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.